Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis

J Immunol. 2013 Feb 1;190(3):1351-9. doi: 10.4049/jimmunol.1200391. Epub 2012 Dec 28.

Abstract

Tumor-targeted vaccines represent a strategy to enhance the graft-versus-leukemia effect after allogeneic blood and marrow transplantation (BMT). We have previously shown that graft-versus-host disease (GVHD) can negatively impact quantitative responses to vaccines. Using a minor histocompatibility Ag-mismatched BMT (B6 → B6 × C3H.SW) followed by adoptive transfer of HY-specific T cells and HY-expressing dendritic cells, we assessed whether GVHD induced by donor lymphocyte infusion (DLI) affects the persistence, proliferation, and survival of vaccine-responding, nonalloantigen reactive T cells. Both CD8(+) and CD4(+) HY-specific T cells undergo less vaccine-driven proliferation in allogeneic recipients with GVHD. Although vaccine-responding CD8(+) T cells show decreased IFN-γ and CD107a production, CD4(+) T cells exhibit increased programmed death 1 and T cell Ig mucin-like domain 3 expression. In addition, the degree of apoptosis in vaccine-responding CD8(+) T cells was higher in the presence of GVHD, but there was no difference in CD4(+) T cell apoptosis. Using Fas ligand-deficient or TRAIL-deficient DLI had no impact on apoptosis of HY-specific T cells. However, perforin-deficient alloreactive DLI induced significantly less apoptosis of vaccine-responding CD8(+) T cells and resulted in enhanced tumor protection. Thus, diminished vaccine responses during GVHD result from impaired proliferation of CD8(+) and CD4(+) T cells responding to vaccination, with an additional contribution from perforin-mediated CD8(+) T cell apoptosis. These results provide important insights toward optimizing vaccine responses after allogeneic BMT.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Adoptive Transfer
  • Animals
  • Animals, Congenic
  • Apoptosis / immunology*
  • CD4-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / immunology*
  • Cancer Vaccines / immunology*
  • Cancer Vaccines / therapeutic use
  • Carcinoma, Transitional Cell / immunology
  • Carcinoma, Transitional Cell / pathology
  • Carcinoma, Transitional Cell / therapy
  • Cell Division
  • Coculture Techniques
  • Dendritic Cells / immunology*
  • Fas Ligand Protein / deficiency
  • Fas Ligand Protein / immunology
  • Female
  • Graft vs Host Disease / immunology*
  • H-Y Antigen / immunology
  • Immunodominant Epitopes / immunology
  • Immunotherapy*
  • Lymphocyte Transfusion
  • Male
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Minor Histocompatibility Antigens / immunology
  • Pore Forming Cytotoxic Proteins / physiology*
  • Radiation Chimera
  • Specific Pathogen-Free Organisms
  • T-Lymphocyte Subsets / immunology*
  • TNF-Related Apoptosis-Inducing Ligand / deficiency
  • TNF-Related Apoptosis-Inducing Ligand / immunology
  • Vaccination*

Substances

  • Cancer Vaccines
  • Fas Ligand Protein
  • Fasl protein, mouse
  • H-Y Antigen
  • Immunodominant Epitopes
  • Minor Histocompatibility Antigens
  • Pore Forming Cytotoxic Proteins
  • TNF-Related Apoptosis-Inducing Ligand
  • Tnfsf10 protein, mouse
  • perforin, mouse